Publications by authors named "J Weisenbach"
Interleukin-18 (IL-18) is an immunostimulatory cytokine that augments antibody-dependent cellular cytotoxicity mediated by human natural killer cells against antibody-coated lymphoma cells in vitro and that has antitumor activity in animal models. Ofatumumab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
View Article and Find Full Text PDFCo-occurrence of and mutations provoke an animal model of AML by epigenetic repression of Wnt pathway antagonists, including and by hyperexpression of encoding Wnt agonist. These affect over-expression and treatment resistance. A comparable epigenetic phenotype was identified among adult AML patients needing novel intervention.
View Article and Find Full Text PDFInterleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20+ lymphoma.
View Article and Find Full Text PDFPurpose: Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activities of rhIL-18 administered at different doses in two different schedules to patients with advanced cancer.
Experimental Design: Cohorts of three to four patients were given escalating doses of rhIL-18 as a 2-h i.
Article Synopsis
- The study investigated the safety, effectiveness, and pharmacokinetics of recombinant human IL-18 (rhIL-18) in patients with advanced cancer through a phase I trial.
- Common side effects reported included chills, fever, and hypotension, but overall, patients tolerated the treatment well without reaching a maximum tolerated dose.
- Biological effects observed after treatment with rhIL-18 included immune activation and increases in specific immune markers, suggesting potential for further research into its antitumor capabilities.